T. Fey

发表

Pharmacological characterization of urinary bladder smooth muscle contractility following partial bladder outlet obstruction in pigs.

M. Gopalakrishnan, M. Brune, S. Buckner, 2006, European journal of pharmacology.

In vitro and in vivo characterization of a novel naphthylamide ATP‐sensitive K+ channel opener, A‐151892

J. Sullivan, C. Shieh, M. Gopalakrishnan, 2004, British journal of pharmacology.

Nephrotoxicity studies of the immunosuppressants tacrolimus (FK506) and ascomycin in rat models.

G. Hsieh, J. Andrews, K. Mollison, 1998, Toxicology.

Discovery of less nephrotoxic FK506 analogs and determining immunophilin dependence of immunosuppressant nephrotoxicity with a novel single-dose rat cisplatin potentiation assay.

G. Hsieh, J. Andrews, K. Mollison, 1997, The Journal of pharmacology and experimental therapeutics.

(−)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-Dioxide (A-278637): A Novel ATP-Sensitive Potassium Channel Opener Efficacious in Suppressing Urinary Bladder Contractions. II. In Vivo Characterization

J. Sullivan, M. Williams, J. Brioni, 2002, Journal of Pharmacology and Experimental Therapeutics.

Hepatic Glucocorticoid Receptor Antagonism Is Sufficient to Reduce Elevated Hepatic Glucose Output and Improve Glucose Control in Animal Models of Type 2 Diabetes

L. Öhman, D. Edgerton, A. Cherrington, 2005, Journal of Pharmacology and Experimental Therapeutics.

3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator.

Xiaoping Zhou, U. Warrior, C. Wegner, 2000, Journal of medicinal chemistry.

A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases.

J. Trevillyan, G. Carter, K. Marsh, 1999, The Journal of investigative dermatology.

Discovery and pharmacological evaluation of growth hormone secretagogue receptor antagonists.

E. Bush, H. Sham, D. Beno, 2006, Journal of medicinal chemistry.

2,4-diaminopyrimidine derivatives as potent growth hormone secretagogue receptor antagonists.

E. Bush, H. Sham, D. Beno, 2006, Journal of medicinal chemistry.

Cardiovascular disease in chronic kidney failure: the role of VDR activators.

M. Nakane, R. Fryer, P. Kroeger, 2006, Current opinion in investigational drugs.

Effects of ATP‐sensitive K+ channel openers and tolterodine on involuntary bladder contractions in a pig model of partial bladder outlet obstruction

J. Sullivan, J. Brioni, M. Gopalakrishnan, 2003, Neurourology and urodynamics.

Pharmacological properties and pro-cognitive effects of ABT-288, a potent and selective histamine H 3 receptor antagonist

K. Browman, J. Sullivan, J. Brioni, 2012 .

Dunaimycins, a new complex of spiroketal 24-membered macrolides with immunosuppressive activity. III. Immunosuppressive activities of dunaimycins.

N. Burres, U. Premachandran, V. A. Thomas, 1991, The Journal of antibiotics.

Pharmacological Properties and Procognitive Effects of ABT-288, a Potent and Selective Histamine H3 Receptor Antagonist

Min Zhang, Min Zhang, K. Browman, 2012, Journal of Pharmacology and Experimental Therapeutics.

High-level C5a gene expression and recovery of recombinant human C5a fromEscherichia coli

G. Carter, J. L. Fox, K. Mollison, 1987, Agents and Actions.

Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.

R. Henry, H. Sham, D. Beno, 2007, Journal of medicinal chemistry.

Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonists.

Thomas Fey, Robin Shapiro, Ju Gao, 2005, Journal of medicinal chemistry.

Synthesis and Structure−Activity Relationships of a Novel Series of 2,3,5,6,7,9-Hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-Dioxide KATP Channel Openers: Discovery of (−)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9- hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-Dioxide (A-278637), a Potent KATP Open

J. Sullivan, R. Henry, J. Brioni, 2004 .

Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases.

P. Wiedeman, J. Trevillyan, K. Marsh, 1998, Current pharmaceutical design.

Identification of receptor-binding residues in the inflammatory complement protein C5a by site-directed mutagenesis.

E. Zuiderweg, R. Edalji, R. Conway, 1989, Proceedings of the National Academy of Sciences of the United States of America.

Improved methods for transplanting split-heart neonatal cardiac grafts into the ear pinna of mice and rats.

G. Hsieh, J. Andrews, K. Mollison, 1998, Journal of pharmacological and toxicological methods.

Chronic treatment with either dexfenfluramine or sibutramine in diet-switched diet-induced obese mice

Thomas Fey, Robin Shapiro, E. Bush, 2006, Endocrine.

Zotarolimus, a Novel Sirolimus Analogue With Potent Anti-proliferative Activity on Coronary Smooth Muscle Cells and Reduced Potential for Systemic Immunosuppression

Yung-wu Chen, J. Trevillyan, G. Carter, 2007, Journal of cardiovascular pharmacology.

Differential effects of Vitamin D analogs on bone formation and resorption

M. Nakane, Y. Li, J. R. Wu-wong, 2006, The Journal of Steroid Biochemistry and Molecular Biology.

Rapamycin analogs with reduced systemic exposure.

P. Wiedeman, J. Trevillyan, G. Carter, 2005, Bioorganic & medicinal chemistry letters.

Digital data analysis techniques for extraction of slosh model parameters

D. D. Kana, J. F. Unruh, Franklin T. Dodge, 1985 .

Pharmacological Properties and Procognitive Effects of ABT-288, a Potent and Selective Histamine H3 Receptor Antagonist

Min Zhang, K. Browman, J. Sullivan, 2012, Journal of Pharmacology and Experimental Therapeutics.

Comparison of FK‐506, Rapamycin, Ascomycin, and Cyclosporine in Mouse Models of Host‐versus‐Graft Disease and Heterotopic Heart Transplantation

K. Mollison, J. Luly, T. Fey, 1993, Annals of the New York Academy of Sciences.